BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10607230)

  • 1. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B.
    Hussain M; Lok AS
    J Viral Hepat; 1999 May; 6(3):183-94. PubMed ID: 10607230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy.
    Stuyver L; Van Geyt C; De Gendt S; Van Reybroeck G; Zoulim F; Leroux-Roels G; Rossau R
    J Clin Microbiol; 2000 Feb; 38(2):702-7. PubMed ID: 10655370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure.
    Günther S; von Breunig F; Santantonio T; Jung MC; Gaeta GB; Fischer L; Sterneck M; Will H
    J Hepatol; 1999 May; 30(5):749-54. PubMed ID: 10365797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
    Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
    J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
    León P; Pozo F; Echevarría JM
    Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):133-7. PubMed ID: 14987532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
    Moriconi F; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Flichman D; Maina AM; Sacco R; Bonino F; Brunetto MR
    J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subclones of drug-resistant hepatitis B virus mutants and the outcome of breakthrough hepatitis in patients treated with lamivudine.
    Kumashiro R; Kuwahara R; Ide T; Koga Y; Arinaga T; Hisamochi A; Ogata K; Tanaka K; Sata M
    Intervirology; 2003; 46(6):350-4. PubMed ID: 14688451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.
    de Man RA; Bartholomeusz AI; Niesters HG; Zondervan PE; Locarnini SA
    J Hepatol; 1998 Oct; 29(4):669-75. PubMed ID: 9824278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.
    Gutfreund KS; Williams M; George R; Bain VG; Ma MM; Yoshida EM; Villeneuve JP; Fischer KP; Tyrrel DL
    J Hepatol; 2000 Sep; 33(3):469-75. PubMed ID: 11020004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir.
    Oon CJ; Chen WN; Lim N; Koh S; Lim GK; Leong AL; Tan GS
    Antiviral Res; 1999 Apr; 41(3):113-8. PubMed ID: 10320044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.
    Mutimer D; Pillay D; Cook P; Ratcliffe D; O'Donnell K; Dowling D; Shaw J; Elias E; Cane PA
    J Infect Dis; 2000 Feb; 181(2):713-6. PubMed ID: 10669360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene.
    Ahn SH; Park YK; Park ES; Kim JH; Kim DH; Lim KH; Jang MS; Choe WH; Ko SY; Sung IK; Kwon SY; Kim KH
    J Virol; 2014 Jun; 88(12):6805-18. PubMed ID: 24696492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.
    Tillmann HL; Trautwein C; Bock T; Böker KH; Jäckel E; Glowienka M; Oldhafer K; Bruns I; Gauthier J; Condreay LD; Raab HR; Manns MP
    Hepatology; 1999 Jul; 30(1):244-56. PubMed ID: 10385663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.
    Bartholomew MM; Jansen RW; Jeffers LJ; Reddy KR; Johnson LC; Bunzendahl H; Condreay LD; Tzakis AG; Schiff ER; Brown NA
    Lancet; 1997 Jan; 349(9044):20-2. PubMed ID: 8988118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients.
    Seta T; Yokosuka O; Imazeki F; Tagawa M; Saisho H
    J Med Virol; 2000 Jan; 60(1):8-16. PubMed ID: 10568756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy.
    Zöllner B; Sterneck M; Wursthorn K; Petersen J; Schröter M; Laufs R; Feucht HH
    J Clin Microbiol; 2005 May; 43(5):2503-5. PubMed ID: 15872296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
    Suzuki F; Kumada H; Nakamura H
    J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants.
    Jardi R; Buti M; Rodriguez-Frias F; Cotrina M; Costa X; Pascual C; Esteban R; Guardia J
    J Virol Methods; 1999 Dec; 83(1-2):181-7. PubMed ID: 10598095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus mutations associated with antiviral therapy.
    Bartholomeusz A; Locarnini S
    J Med Virol; 2006; 78 Suppl 1():S52-5. PubMed ID: 16622878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.